Annals of the rheumatic diseases
-
Randomized Controlled Trial Multicenter Study
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. ⋯ In patients with rheumatoid arthritis and an inadequate response or intolerance to conventional synthetic DMARDs, baricitinib was associated with clinical improvement and inhibition of progression of radiographic joint damage.